Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
We are a biotechnology firm in the clinical stage, dedicated to unraveling biological complexities through the integration of cutting-edge innovations spanning biology, chemistry, automation, machine learning, and engineering, all aimed at revolutionizing drug discovery. Our approach allows for enhanced precision in biological manipulation with advanced techniques like CRISPR genome editing and synthetic biology. We also achieve reliable automation for intricate laboratory processes at an unprecedented scale through the use of sophisticated robotics. By employing neural network architectures, we conduct iterative analyses and draw insights from extensive, intricate datasets generated in-house. Furthermore, we are boosting the adaptability of high-performance computing capabilities through cloud-based solutions. Our initiative harnesses new technologies to foster continuous learning cycles around our datasets, establishing us as a next-generation biopharmaceutical enterprise. This is achieved through a harmonious integration of hardware, software, and data, all dedicated to the industrialization of drug discovery. We are transforming the conventional drug discovery pipeline and boast one of the most extensive, diverse, and in-depth pipelines among technology-driven drug discovery companies. Ultimately, our mission is to enhance the efficiency and effectiveness of drug development, paving the way for breakthrough therapies.
Description
Healthcare providers and pharmaceutical firms leverage RetinAI's software platform to effectively manage their data while benefiting from enhanced insights through automated AI analysis, thereby optimizing both clinical and research workflows. This unified data platform allows users to access and manage their information from any location at any time. It supports a variety of formats, including DICOM-compliant and proprietary types. By utilizing AI, data is harmonized, organized, aggregated, and analyzed on a large scale to uncover insights related to disease progression, treatment outcomes, and predictions of disease advancement. Additionally, the platform facilitates collaborative research within organizations by providing secure cloud-based access to data. It serves as a central hub for data, medical, and digital teams. Users can conduct AI-driven analysis on their OCT volumes, focusing on layer and fluid segmentation. Immediate evaluations can be performed to consolidate insights into a single platform. Collaborators can be swiftly invited to access and interact with datasets according to specified permission levels, fostering a more integrated research environment. This comprehensive approach not only streamlines data management but also enhances collaborative efforts across different teams and disciplines.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Recursion
Country
United States
Website
www.recursion.com
Vendor Details
Company Name
RetinAI
Country
Switzerland
Website
www.retinai.com